This broad strategic collaboration to discover, develop and commercialize therapies for the treatment of cancer was established in July 2004. The collaboration encompasses the development of therapeutic antibodies and
small molecule drugs against over-expressed cell-surface proteins that have been associated with cancer and validated as therapeutic targets through proteomics research at Celera. It pairs Celera's proteomics and target discovery efforts with Abbott's drug research
development, manufacturing and commercialization expertise. Celera will receive payments from Abbott, contingent on the successful completion of certain preclinical milestones. In addition, Abbott and
Celera may elect to jointly fund clinical development and
commercialization of the resulting therapeutic products and would share any profits resulting from commercialization. Abbott has responsibility for the commercialization of jointly funded collaboration products.
Abbott now has a total of six targets under investigation from the strategic collaboration established between Celera and Abbott to discover, develop and commercialize therapies for the treatment of cancer.
This research collaboration to jointly discover and develop antibody-based therapies for cancer was established in July 2004. Celera and Seattle Genetics will jointly designate a number of cell-surface proteins discovered and validated through Celera's proprietary proteomic platform as antigen targets. Seattle Genetics
will carry out initial screening to generate and select the appropriate corresponding antibodies, or antibody-drug-conjugates (ADC), for joint development and
commercialization. Celera and Seattle Genetics will co-fund preclinical and clinical product development and will share any profits resulting from collaboration products. Products developed under the collaboration may include either monoclonal antibodies or antibodies
linked to potent cell-killing payloads utilizing Seattle Genetics’ antibody-drug-conjugate technology.
In June 2006, Celera announced the formation of a strategic collaboration with Medarex to discover and develop fully human antibodies for the potential treatment of multiple cancer indications. The collaboration will encompass the development of therapeutic antibodies against proteins identified by Celera’s proteomic research discovery efforts as being over-expressed on the surface of tumor cells and subsequently validated through additional research at Celera. The collaboration combines Celera’s ability to discover and validate novel targets for oncology with Medarex's expertise in the development of fully human antibody therapeutics. Under the collaboration, Celera and Medarex plan to jointly select targets from Celera’s portfolio of novel cancer targets. Medarex expects to generate fully human monoclonal antibodies against these targets using its proprietary UltiMAb Human Antibody Development System®, and the two companies expect to jointly carry out initial validation studies. The two companies plan to alternate the selection of antigen-antibody research programs to further develop and commercialize the antibodies independently. The selecting party will have full development and commercialization rights to products arising from its selected research programs, and the other party will be entitled to receive milestone payments if milestones are achieved and royalties on commercial sales of any such products. The selecting company may develop antibodies generated under this collaboration internally or through external partners. Other financial terms of the agreement were not disclosed.
